$30m Bahrain Pharma adds to regional strength in pharmaceuticals production

$30m Bahrain Pharma adds to regional strength in pharmaceuticals production

Bahrain Pharma, the $30m specialty healthcare manufacturer founded as a key pillar of Bahrain's pharmaceuticals and healthcare strategy, has secured approval on the 25th of June 2020, to begin trial production.



Commercial production is expected to begin in September of this year. The pharmaceutical company has been licensed by Bahrain's National Health Regulatory Authority (NHRA) to produce gel capsule and soluble syrups, but has the capacity to rapidly move to a much wider variety of product types. As it moves into the production phase, Bahrain Pharma will create Bahrain's first high-value, high-skilled pharmaceutical manufacturing jobs.



Current estimates suggest that the pharmaceutical industry across the GCC is worth approximately $20 billion making it a growing contributor to regional GDP. However, 80 per cent of pharmaceutical products are imported from outside the region, and it is clear that balancing this ratio could spell a significant opportunity for local markets.



Mr. Osama Al Arayedh, Undersecretary for Industrial Affairs at the Ministry of Industry, Commerce, and Tourism, said: "With more than 80 per cent of pharmaceutical products imported from outside the region, the GCC offers a compelling case for the setup of regional distribution hubs and in-market production facilities. Bahrain offers healthcare manufacturers an excellent